Mechanisms of Estrogen-Induced Venous Thromboembolism

Thrombosis Research

Volumn 126, Issue 1, 2010, Pages 5-11

  Tchaikovski, Svetlana N ^a   Rosing, Jan ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ALPHA 2 MACROGLOBULIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9; CYPROTERONE; CYPROTERONE ACETATE; DESOGESTREL; DROSPIRENONE; ESTROGEN; ETHINYLESTRADIOL; FIBRINOGEN; GESTODENE; LEVONORGESTREL; MESTRANOL; NORETYNODREL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN; SEX HORMONE BINDING PROTEIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRYPSIN INHIBITOR; BLOOD CLOTTING FACTOR; CONTRACEPTIVE AGENT; ORAL CONTRACEPTIVE AGENT;

ACTIVATED PROTEIN C RESISTANCE; ANTITHROMBIN DEFICIENCY; BLEEDING; BLOOD GROUP; DISEASE ASSOCIATION; DISEASE MARKER; HEMOSTASIS; HUMAN; IMMOBILIZATION; INJURY; INTRAUTERINE CONTRACEPTIVE DEVICE; OBESITY; ORAL CONTRACEPTION; PILL; PRESCRIPTION; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PROTEIN C DEFICIENCY; PROTEIN DEGRADATION; PROTEIN S DEFICIENCY; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS; SMOKING; VAGINA RING; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; CONTRACEPTION; DRUG EFFECTS; FEMALE; RISK; VEIN THROMBOSIS;

BLOOD COAGULATION FACTORS; CONTRACEPTION; CONTRACEPTIVE AGENTS; CONTRACEPTIVES, ORAL; ESTROGENS; FEMALE; HEMOSTASIS; HUMANS; LEVONORGESTREL; RISK; RISK FACTORS; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 77953121511     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.01.045     Document Type: Review

References (77)

1. WHO scientific group meeting on cardiovascular disease and steroid hormone contraceptives. Wkly Epidemiol Rec 1997, 72:361-363.
2. Vandenbroucke J.P., Koster T., Briet E., et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344 (1994) 1453-1457
3. Jordan W. Pulmonary embolism. Lancet 18 (1961) 1146-1147
4. Tyler E.T. Oral contraception and venous thrombosis. Jama 185 (1963) 131-132
5. Connell EB: Contraception in the prepill era. Contraception 1999, 59:7S-10S.
6. Gerstman B.B., Piper J.M., Tomita D.K., et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 133 (1991) 32-37
7. Skouby S.O., and Petersen K.R. Clinical experience with the recently developed progestogens. Int J Fertil 36 Suppl 1 (1991) 32-37
8. Jick H., Jick S.S., Gurewich V., et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346 (1995) 1589-1593
9. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995, 346:1582-1588.
10. de Jong-van den Berg L., Tobi H., Bijker B., et al. Influence of the third generation pill controversy on prescriptions for oral contraceptives among first time users: population based study. Bmj 326 (2003) 254
11. Herings R.M., Urquhart J., and Leufkens H.G. Venous thromboembolism among new users of different oral contraceptives. Lancet 354 (1999) 127-128
12. Bloemenkamp K.W., Rosendaal F.R., Helmerhorst F.M., et al. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 160 (2000) 49-52
13. van Hylckama Vlieg A., Helmerhorst F.M., Vandenbroucke J.P., et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. Bmj 339 (2009) b2921
14. Muhn P., Fuhrmann U., Fritzemeier K.H., et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci 761 (1995) 311-335
15. Vasilakis-Scaramozza C., and Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 358 (2001) 1427-1429
16. Odlind V., Milsom I., Persson I., et al. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?. Acta Obstet Gynecol Scand 81 (2002) 482-490
17. Kemmeren J.M., Algra A., Meijers J.C., et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood 103 (2004) 927-933
18. Goebelsmann U., Mashchak C.A., and Mishell Jr. D.R. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet Gynecol 151 (1985) 868-877
19. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 51 (1996) 188-215
20. Tans G., Curvers J., Middeldorp S., et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 84 (2000) 15-21
21. Middeldorp S., Meijers J.C., van den Ende A.E., et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 84 (2000) 4-8
22. Meijers J.C., Middeldorp S., Tekelenburg W., et al. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost 84 (2000) 9-14
23. Johnson J.V., Lowell J., Badger G.J., et al. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstet Gynecol 111 (2008) 278-284
24. Harris G.M., Stendt C.L., Vollenhoven B.J., et al. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. Am J Hematol 60 (1999) 175-180
25. Rosendaal F.R., and Reitsma P.H. Genetics of venous thrombosis. J Thromb Haemost 7 Suppl 1 (2009) 301-304
26. Martinelli I., Mannucci P.M., De Stefano V., et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 92 (1998) 2353-2358
27. Poort S.R., Rosendaal F.R., Reitsma P.H., et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 (1996) 3698-3703
28. Koster T., Rosendaal F.R., de Ronde H., et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342 (1993) 1503-1506
29. Jick H., Slone D., Westerholm B., et al. Venous thromboembolic disease and ABO blood type. A cooperative study. Lancet 1 (1969) 539-542
30. Grunbacher G., Weger W., Marx-Neuhold E., et al. The fibrinogen gamma (FGG) 10034C>T polymorphism is associated with venous thrombosis. Thromb Res 121 (2007) 33-36
31. Dahlback B., Carlsson M., and Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 90 (1993) 1004-1008
32. Bertina R.M., Koeleman B.P., Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994) 64-67
33. Gennari L.C., Blanco A.N., Dominguez M.P., et al. Endogenous or exogenous coagulation factor level and the response to activated protein C. Thromb Res 118 (2006) 269-273
34. de Visser M.C. van Hylckama Vlieg A, Tans G, et al: Determinants of the APTT- and ETP-based APC sensitivity tests. J Thromb Haemost 3 (2005) 1488-1494
35. Tans G. van Hylckama Vlieg A, Thomassen MC, et al: Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 122 (2003) 465-470
36. de Visser M.C., Rosendaal F.R., and Bertina R.M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 93 (1999) 1271-1276
37. Rodeghiero F., and Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 130 (1999) 643-650
38. Kamphuisen P.W., Eikenboom J.C., Rosendaal F.R., et al. High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br J Haematol 115 (2001) 156-158
39. van Hylckama Vlieg A., van der Linden I.K., Bertina R.M., et al. High levels of factor IX increase the risk of venous thrombosis. Blood 95 (2000) 3678-3682
40. Meijers J.C., Tekelenburg W.L., Bouma B.N., et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 342 (2000) 696-701
41. van Hylckama Vlieg A., and Rosendaal F.R. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost 1 (2003) 2677-2678
42. Dahm A., Van Hylckama Vlieg A., Bendz B., et al. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 101 (2003) 4387-4392
43. Rosendaal F.R. Venous thrombosis: a multicausal disease. Lancet 353 (1999) 1167-1173
44. Conard J. Biological coagulation findings in third-generation oral contraceptives. Hum Reprod Update 5 (1999) 672-680
45. Koenen R.R., Christella M., Thomassen L.G., et al. Effect of oral contraceptives on the anticoagulant activity of protein S in plasma. Thromb Haemost 93 (2005) 853-859
46. Olivieri O., Friso S., Manzato F., et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 91 (1995) 465-470
47. Rosing J., Tans G., Nicolaes G.A., et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 97 (1997) 233-238
48. Curvers J., Thomassen M.C., Rimmer J., et al. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost 88 (2002) 5-11
49. Hoibraaten E., Mowinckel M.C., de Ronde H., et al. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol 115 (2001) 415-420
50. Vandenbroucke J.P., Helmerhorst F.M., Bloemenkamp K.W., et al. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol 177 (1997) 887-891
51. Dielis A.W., Castoldi E., Spronk H.M., et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 6 (2008) 125-131
52. Tchaikovski S.N., van Vliet H.A., Thomassen M.C., et al. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost 98 (2007) 1350-1356
53. Malm J., Laurell M., and Dahlback B. Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol 68 (1988) 437-443
54. van Vliet H.A., Bertina R.M., Dahm A.E., et al. Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost 6 (2008) 346-351
55. Dahm A.E., Sandset P.M., and Rosendaal F.R. The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1. J Thromb Haemost 6 (2008) 393-395
56. Tchaikovski S.N., van Vlijmen B.J., Cleuren A.C., et al. Pregnancy-associated changes in the hemostatic system in wild-type and factor V Leiden mice. J Thromb Haemost 7 (2009) 312-318
57. Rosing J., Hoekema L., Nicolaes G.A., et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 270 (1995) 27852-27858
58. Hackeng T.M., Maurissen L.F., Castoldi E., et al. Regulation of TFPI function by protein S. J Thromb Haemost 7 Suppl 1 (2009) 165-168
59. Humpel M., Wendt H., Pommerenke G., et al. Investigations of pharmacokinetics of levonorgestrel to specific consideration of a possible first-pass effect in women. Contraception 17 (1978) 207-220
60. Jick S.S., Kaye J.A., Russmann S., et al. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception 73 (2006) 566-570
61. Cole J.A., Norman H., Doherty M., et al. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 109 (2007) 339-346
62. Kluft C., Meijer P., LaGuardia K.D., et al. Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables. Contraception 77 (2008) 77-83
63. Fleischer K., van Vliet H.A., Rosendaal F.R., et al. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study. Thromb Res 123 (2009) 429-435
64. Dahm A.E., Iversen N., Birkenes B., et al. Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1. BMC Cardiovasc Disord 6 (2006) 40
65. van den Heuvel M.W., van Bragt A.J., Alnabawy A.K., et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 72 (2005) 168-174
66. Devineni D., Skee D., Vaccaro N., et al. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. J Clin Pharmacol 47 (2007) 497-509
67. Vasilakis C., and Jick H. del Mar Melero-Montes M: Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 354 (1999) 1610-1611
68. Heinemann L.A., Assmann A., DoMinh T., et al. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 4 (1999) 67-73
69. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998, 57:315-324.
70. van Vliet H.A., Tchaikovski S.N., Rosendaal F.R., et al. The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC). Thromb Haemost 101 (2009) 691-695
71. Walker I.D. Factor V Leiden: should all women be screened prior to commencing the contraceptive pill?. Blood Rev 13 (1999) 8-13
72. WHO: Medical eligibility criteria for contraceptive use.
73. van Vliet H.A., Frolich M., Christella M., et al. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum Reprod 20 (2005) 563-568
74. Rosing J., Middeldorp S., Curvers J., et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 354 (1999) 2036-2040
75. Curvers J., Thomassen M.C., Nicolaes G.A., et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol 105 (1999) 88-94
76. Alhenc-Gelas M., Plu-Bureau G., Guillonneau S., et al. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives. J Thromb Haemost 2 (2004) 1594-1600
77. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception 2003, 67:173-185.